title: Vision related quality of life and topical glaucoma treatment side effects.
abstract: BACKGROUND
  Local tolerance of topical glaucoma treatment is important to achieve a good compliance. The aim of this study was to evaluate the consequences of local anti-glaucoma drug side effects on the vision-related quality of life (QoL).
  
  
  METHODS
  A mail survey was sent to 20,000 homes of a panel representative of the French population asking whether one member of the family was suffering from ocular hypertension (OHT) or glaucoma. (POAG) A computer-assisted telephone interviewing system was used to confirm self-reported glaucoma, to describe the disease and its treatment, and medical item consumption. Vision-related QoL was assessed with the NEI-VFQ-25 (National Eye Institute Visual - Function Questionnaire) and local tolerance with the COMTOL (Comparison of Ophthalmic Medications for TOLerability).
  
  
  RESULTS
  13,352 homes (66.7%) answered the mail. 581 people declared they were suffering from glaucoma or OHT. Prevalence was 1.8%, increasing with age. 204 patients were selected at random Their NEI-VFQ-25 global score showed an overall good QoL. Two domain scores showed some deterioration: general health and driving. 62.4% of the patients cited at least one local side effect. 25.4% had burning, 20.8% blurred vision and 20.2% tearing. Poor vision related QoL was associated with the presence of local side effects leading to poor perceived treatment satisfaction. Dissatisfied patients visited their ophthalmologist more frequently.
  
  
  CONCLUSIONS
  Based on a representative French sample, poor vision related QoL was associated with topical drug side effects that also impact patient satisfaction and compliance. Longitudinal data collection should be performed to confirm our findings.
authors.affiliation: Quinze-Vingts, Centre Hospitalier National d'Ophtalmologie, 28 Rue de Charenton, F-75571 Paris Cedex 12, France. j.p.nordmann@quinze-vingts.fr
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Nordmann
authors.forename: Nadia
authors.initials: N
authors.lastname: Auzanneau
authors.forename: Séverine
authors.initials: S
authors.lastname: Ricard
authors.forename: Gilles
authors.initials: G
authors.lastname: Berdeaux
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D005602:France / Q000453:epidemiology; D005901:Glaucoma / Q000188:drug therapy*; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D015995:Prevalence; D011788:Quality of Life; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents